The efficacy and tolerability of bupropion in the treatment of major depressive disorder

Clinical Drug Investigation

Volumn 31, Issue SUPPL. 1, 2011, Pages 5-17

  Moreira, Ricardo ^a,b  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

^b University of Porto   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMFEPRAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; DOPAMINE UPTAKE INHIBITOR; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PLACEBO; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; VENLAFAXINE;

ANOREXIA; ANXIETY; APPETITE; CANADA; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; EUROPE; FATIGUE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HEADACHE; HUMAN; HYPERHIDROSIS; INSOMNIA; MAJOR DEPRESSION; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; QUESTIONNAIRE; RELAPSE; REMISSION; REVIEW; SCORING SYSTEM; SEDATION; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT; SOMNOLENCE; SUSTAINED RELEASE FORMULATION; SWEATING; TACHYCARDIA; TREATMENT OUTCOME; UNITED STATES; WEIGHT GAIN; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; DEPRESSIVE DISORDER, MAJOR; DOPAMINE UPTAKE INHIBITORS; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 80054867307     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/1159616-S0-000000000-00000     Document Type: Review

References (74)

1. Langlieb AM, Guico-Pabia CJ. Beyond symptomatic improvement: assessing real-world outcomes in patients with major depressive disorder. Prim Care Companion J Clin Psychiatry 2010; 12 (2): e1-e14
2. National Institute for Health and Clinical Excellence. Depression: the treatment and management of depression in adults (updated edition). CG90. London, UK: The British Psychological Society and the Royal College of Psychiatrists, 2009. Available from: http://guidance.nice.org.uk/CG90
3. Hasin DS, Goodwin RD, Stinson FS, et al. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 2005 Oct; 62 (10): 1097-106 (Pubitemid 41396935)
4. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005 Jun; 62 (6): 617-27 (Pubitemid 40973437)
5. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005 Jun; 62 (6): 593-602 (Pubitemid 40973434)
6. Eaton WW, Martins SS, Nestadt G, et al. The burden of mental disorders. Epidemiol Rev 2008; 30: 1-14
7. King M, Nazareth I, Levy G, et al. Prevalence of common mental disorders in general practice attendees across Europe. Br J Psychiatry 2008May; 192 (5): 362-7
8. World Health Organization. Global Health Risks: Mortality and burden of disease attributable to selected major risks. Geneva, Switzerland: WHO Press, 2009. Available from: www.who.int/healthinfo/global-burden-disease/ GlobalHealthRisks-report-full.pdf
9. Griffiths KM, Crisp DA, Jorm AF, et al. Does stigma predict a belief in dealing with depression alone? J Affect Disord 2011; 132 (3): 413-7
10. World Health Organization. The Global Burden of Disease: 2004 Update. Geneva, Switzerland: WHO Press, 2008. Available from: http://www.who.int/ healthinfo/global-burden-disease/GBD-report-2004update-full.pdf
11. Nutt DJ, Davidson JR, Gelenberg AJ, et al. International consensus statement on major depressive disorder [abstract]. J Clin Psychiatry 2010; 71 Suppl. E1: e08
12. Suehs B, Argo TR, Bendele SD, et al. Texas Medication Algorithm Project Procedural Manual: Major Depressive Disorder Algorithms. Austin, TX: Texas Department of State Health Services, 2008. Available from: http://www.dshs. state.tx.us/mhprograms/pdf/TIMA-MDD-Manual-080608.pdf
13. Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 2007; 8 (2): 67-104 (Pubitemid 46690921)
14. Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice guideline for the: Treatment of patients with major depressive disorder. Third edition. Arlington, VA: American Psychiatric Association (APA), 2010. Available from: http://www.psychiatryonline.com/pracGuide/pracGuidehome.aspx
15. Nierenberg AA, Petersen TJ, Alpert JE. Prevention of relapse and recurrence in depression: the role of long-term pharmacotherapy and psychotherapy. J Clin Psychiatry 2003; 64 Suppl. 15: 13-17 (Pubitemid 37464492)
16. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidencebased guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008 Jun; 22 (4): 343-96 (Pubitemid 351989984)
17. Davidson JR. Major depressive disorder treatment guidelines in America and Europe [abstract]. J Clin Psychiatry 2010; 71 Suppl. E1: e04
18. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009 Oct; 117 Suppl. 1: S26-43
19. Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008 Nov 18; 149 (10): 734-50
20. Damaj MI, Carroll FI, Eaton JB, et al. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. MolPharmacol 2004 Sep; 66 (3): 675-82 (Pubitemid 39329267)
21. Stahl SM, Pradko JF, Haight BR, et al. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Prim Care Companion J Clin Psychiatry 2004; 6 (4): 159-66
22. Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatry 1999; 60 Suppl. 4: 4-11; discussion 2-3
23. GlaxoSmithKline. Wellbutrin XR (bupropion hydrochloride extended-release tablets): US prescribing information [online]. 2008
24. GlaxoSmithKline. Wellbutrin (bupropion hydrochloride): US prescribing information [online]. 2010
25. Dhillon S, Yang LP, Curran MP. Bupropion: a review of its use in the management of major depressive disorder. Drugs 2008; 68 (5): 653-89 (Pubitemid 351484811)
26. Lineberry CG, Johnston JA, Raymond RN, et al. A fixeddose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. J Clin Psychiatry 1990 May; 51 (5): 194-9 (Pubitemid 20159096)
27. Coleman CC, Cunningham LA, Foster VJ, et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 1999 Dec; 11 (4): 205-15
28. Coleman CC, King BR, Bolden-Watson C, et al. A placebocontrolled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. ClinTher 2001 Jul; 23 (7): 1040-58 (Pubitemid 32709626)
29. Croft H, Settle Jr E, Houser T, et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. ClinTher 1999 Apr; 21 (4): 643-58 (Pubitemid 29252088)
30. Reimherr FW, Cunningham LA, Batey SR, et al. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients. ClinTher 1998 May-Jun; 20 (3): 505-16 (Pubitemid 28343503)
31. Weihs KL, Settle Jr EC, Batey SR, et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 2000 Mar; 61 (3): 196-202 (Pubitemid 30214516)
32. Weihs KL, Houser TL, Batey SR, et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry 2002 May 1; 51 (9): 753-61 (Pubitemid 34450811)
33. Jefferson JW, Rush AJ, Nelson JC, et al. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebocontrolled study. J Clin Psychiatry 2006 Jun; 67 (6): 865-73 (Pubitemid 44049084)
34. Hewett K, Chrzanowski W, Jokinen R, et al. Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder. J Psychopharmacol 2010 Apr; 24 (4): 521-9
35. Clayton AH, Croft HA, Horrigan JP, et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 2006 May; 67 (5): 736-46 (Pubitemid 43946180)
36. Thase ME, Clayton AH, Chrzanowski W. Bupropion extended release and venlafaxine extended release for the treatment of depression: results from three multicenter trials [abstract no. 146 plus poster]. 14th Congress of Psychiatry of the Association of European Psychiatrists. Nice, 2006
37. Thase ME, Clayton AH, Haight BR, et al. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J ClinPsychopharmacol 2006 Oct; 26 (5): 482-8 (Pubitemid 44401468)
38. Papakostas GI, Kornstein SG, Clayton AH, et al. Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender-age interactions. Intl Clin Psychopharmacol 2007 Jul; 22 (4): 226-9 (Pubitemid 46801946)
39. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009 Feb 28; 373 (9665): 746-58
40. Feighner JP, Gardner EA, Johnston JA, et al. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry 1991 Aug; 52 (8): 329-35
41. Masco HL, Kiev A, Holloman LC, et al. Safety and efficacy of bupropion and nortriptyline in outpatients with depression. Curr Ther Res 1994; 55 (7): 851-63 (Pubitemid 24231265)
42. Mendels J, Amin MM, Chouinard G, et al. A comparative study of bupropion and amitriptyline in depressed outpatients. J Clin Psychiatry 1983 May; 44 (5 Pt 2): 118-20 (Pubitemid 13088849)
43. Feighner J, Hendrickson G, Miller L, et al. Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder. J Clin Psychopharmacol 1986 Feb; 6 (1): 27-32 (Pubitemid 16164979)
44. Weisler RH, Johnston JA, Lineberry CG, et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol 1994 Jun; 14 (3): 170-9 (Pubitemid 24182183)
45. Kavoussi RJ, Segraves RT, Hughes AR, et al. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997 Dec; 58 (12): 532-7 (Pubitemid 28100273)
46. Cipriani A, Santilli C, Furukawa TA, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009; (2): CD006532
47. Cipriani A, La Ferla T, Furukawa TA, et al. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev 2010; 4: CD006117
48. Hewett K, Chrzanowski W, Schmitz M, et al. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol 2009 Jul; 23 (5): 531-8
49. Bauer M, Tharmanathan P, Volz HP, et al. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci 2009 Apr; 259 (3): 172-85
50. Hewett K, Gee MD, Krishen A, et al. Double-blind, placebocontrolled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol 2010 Aug; 24 (8): 1209-16
51. Papakostas GI, Trivedi MH, Alpert JE, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: ameta-analysis of individual patient data from 10 double-blind, randomized clinical trials. J Psychiatr Res 2008 Jan; 42 (2): 134-40 (Pubitemid 350061259)
52. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006 Mar 23; 354 (12): 1231-42
53. Papakostas GI, Fava M, Thase ME. Treatment of SSRIresistant depression: a meta-analysis comparing withinversus across-class switches. Biol Psychiatry 2008 Apr 1; 63 (7): 699-704 (Pubitemid 351329277)
54. Blier P, Gobbi G, Turcotte JE, et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 2009 Jul; 19 (7): 457-65
55. Blier P, Ward HE, Tremblay P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010 Mar; 167 (3): 281-8
56. Maes M, Libbrecht I, van Hunsel F, et al. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol 1999 Apr; 19 (2): 177-82 (Pubitemid 29161964)
57. Nelson JC, Mazure CM, Jatlow PI, et al. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 2004 Feb 1; 55 (3): 296-300 (Pubitemid 38117167)
58. Rojo JE, Ros S, Aguera L, et al. Combined antidepressants: clinical experience. Acta Psychiatr Scand Suppl 2005; 112 Suppl. 428: 25-31 (Pubitemid 41789708)
59. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006 Mar 23; 354 (12): 1243-52
60. Maron E, Eller T, Vasar V, et al. Effects of bupropion augmentation in escitalopram-resistant patients with major depressive disorder: an open-label, naturalistic study. J Clin Psychiatry 2009 Jul; 70 (7): 1054-6
61. GlaxoSmithKline. Wellbutrin SR (bupropion hydrochloride sustained-release tablets): US prescribing information [online]. 2010
62. Croft HA, Wightman D, Hewett K. Additional data on the safety and tolerability of bupropion extended-release: newly accumulated data extends previous findings in placebo controlled clinical trials [abstract no. NR484 plus poster]. 159th Annual Meeting of the American Psychiatric Association. Toronto (ON), 2006
63. Fava M, Rush AJ, Thase ME, et al. 15 Years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 2005; 7 (3): 106-13 (Pubitemid 41783226)
64. Wightman DS, Foster VJ, Krishen A, et al. Meta-analysis of suicidality in placebo-controlled clinical trials of adults taking bupropion. Prim Care Companion J Clin Psychiatry 2010; 12 (5): e1-e8
65. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin- Psychopharmacol 2009 Jun; 29 (3): 259-66
66. Segraves RT, Kavoussi R, Hughes AR, et al. Evaluation of sexual functioning in depressed outpatients: a double-blind comparison of sustained-release bupropion and sertraline treatment. J Clin Psychopharmacol 2000 Apr; 20 (2): 122-8 (Pubitemid 30202352)
67. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002 Apr; 63 (4): 357-66 (Pubitemid 34456365)
68. Clayton AH, Warnock JK, Kornstein SG, et al. A placebocontrolled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 2004 Jan; 65 (1): 62-7
69. Masand PS, Ashton AK, Gupta S, et al. Sustained-release bupropion for selective serotonin reuptake inhibitorinduced sexual dysfunction: a randomized, double-blind, placebo-controlled, parallel-group study. Am J Psychiatry 2001 May; 158 (5): 805-7 (Pubitemid 32429853)
70. Demyttenaere K, Jaspers L. Review: Bupropion and SSRIinduced side effects. J Psychopharmacol 2008 Sep; 22 (7): 792-804
71. Nieuwstraten CE, Dolovich LR. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression. Ann Pharmacother 2001 Dec; 35 (12): 1608-13 (Pubitemid 34027464)
72. Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005 Aug; 66 (8): 974-81 (Pubitemid 41191788)
73. Settle EC, Stahl SM, Batey SR, et al. Safety profile of sustained- release bupropion in depression: results of three clinical trials. ClinTher 1999 Mar; 21 (3): 454-63 (Pubitemid 29198034)
74. Papakostas GI, Nutt DJ, Hallett LA, et al. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry 2006 Dec 15; 60 (12): 1350-5 (Pubitemid 44838537)